Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison

Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Risk & Volatility

Unicycive Therapeutics has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Valuation and Earnings

This table compares Unicycive Therapeutics and Aprea Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	25.44	-$30.54 million	($1.19)	-0.39
Aprea Therapeutics	$580,000.00	29.30	-$14.29 million	($3.32)	-0.94

Aprea Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Unicycive Therapeutics and Aprea Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0	0	4	1	3.20
Aprea Therapeutics	0	0	2	0	3.00

Unicycive Therapeutics presently has a consensus price target of $5.13, suggesting a potential upside of 1,014.13%. Aprea Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 395.21%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Aprea Therapeutics.

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-34.98%
Aprea Therapeutics	-1,012.37%	-56.38%	-46.35%

Summary

Unicycive Therapeutics beats Aprea Therapeutics on 13 of the 15 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.